Literature DB >> 17392615

PARP inhibitors and heart failure--translational medicine caught in the act.

George W Booz1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392615     DOI: 10.1111/j.1527-5299.2007.06595.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN: 1527-5299


× No keyword cloud information.
  5 in total

Review 1.  CB1 cannabinoid receptor inhibition: promising approach for heart failure?

Authors:  Partha Mukhopadhyay; Rajesh Mohanraj; Sándor Bátkai; Pál Pacher
Journal:  Congest Heart Fail       Date:  2008 Nov-Dec

2.  Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats.

Authors:  Sevil Korkmaz-Icöz; Bartosz Szczesny; Michela Marcatti; Shiliang Li; Mihály Ruppert; Felix Lasitschka; Sivakkanan Loganathan; Csaba Szabó; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-10-02       Impact factor: 8.739

Review 3.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007

Review 4.  NAD+ Metabolism as an Emerging Therapeutic Target for Cardiovascular Diseases Associated With Sudden Cardiac Death.

Authors:  Weiyi Xu; Le Li; Lilei Zhang
Journal:  Front Physiol       Date:  2020-08-13       Impact factor: 4.566

5.  Fingolimod (FTY720) Preserves High Energy Phosphates and Improves Cardiac Function in Heterotopic Heart Transplantation Model.

Authors:  Naseer Ahmed; Javeria Farooq; Soban Sadiq; Sultan Ayoub Meo; Azam Jan; Faisal H Cheema; Giuseppe Faggian; Alessio Rungatscher
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.